E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 11/4/2005 in the Prospect News Biotech Daily.

Jefferies maintains PDI at hold rating

PDI, Inc. was maintained by Jefferies & Co. Inc. at a hold rating with a $12 price target after PDI reported weaker- than-expected third-quarter losses, in-line revenue and higher costs than anticipated. Jefferies said the newly named CEO is taking a hard look at cost-cutting opportunities, including terminating unprofitable businesses, but those benefits aren't likely to show until 2006. PDI's long downward slide makes it vulnerable in competitive bidding situations. Shares of the Saddle Ridge, N.J. biopharmaceutical sales and marketing company were down $0.66, or 4.81%, at $13.08 on volume of 217,550 shares versus the three-month running average of 54,013.6 shares.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.